Project Grant HT94252410616
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$714K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This Project Grant award of $624,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research on fusion-driven pediatric rhabdomyosarcomas at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The research, spanning from September 1, 2025 to August 31, 2027, aims to conduct comprehensive in vivo phenotyping to transform healthcare for military service members and the broader...
The Project Grant award of $624,000 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Research Institute at Nationwide Children's Hospital. The funding supports a project titled "SPLICING UP PD-L1 FOR IMMUNOTHERAPY ENHANCEMENT IN PEDIATRIC NEURONAL TUMORS" over a two-year period from September 30, 2023 to September 29, 2025. The goal is to conduct research to advance immunotherapy approaches...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...
This federal Project Grant award of $1,317,452.00 from the Defense Health Agency (DHA) was provided to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 4-year research project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" that commenced on August 15, 2023 and is scheduled for completion by August 14, 2027. The Research Institute at Nationwide Children's...
The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
The Research Institute at Nationwide Children's Hospital will receive $8.5 million over four years from the Defense Health Agency under the Military Medical Research and Development program to compare the long-term efficacy of tissue-engineered vascular grafts versus polytetrafluoroethylene conduits using an established preclinical model. The award, issued on September 30, 2022, will support research to transform military and public health care through innovative medical solutions for...
The Defense Health Agency awarded a $697,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Murdoch Children's Research Institute in Australia. The grant, awarded on July 15, 2024, will fund a 3-year research project titled "BRAIN CHARTS IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1". The project aims to conduct biomedical research to better understand and characterize brain development in children and adolescents with...
This $1,354,428 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a family-centered e-health intervention to promote patient and caregiver well-being in adolescent and emerging adult pediatric brain tumor survivors. The grant was awarded to the Children's Hospital Medical Center in Cincinnati, Ohio, which will serve as the prime awardee. The project duration is from September 1, 2024 to August 31, 2028. The...
The Department of the Army Medical Command awarded $1.393 million to the Children's Research Institute under the Military Medical Research and Development federal grant program (CFDA 12.420) to support an early-phase study evaluating MEK and MDM2 inhibition in patients with neurofibromatosis type 1 and premalignant and malignant peripheral nerve sheath tumors. The Children's Research Institute will conduct the clinical trial through September 2026 to investigate medical solutions for...
This federal Project Grant award of $656,513.00, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify germline modifiers of neurofibromatosis type 1 (NF1) tumors. The primary grantee, Childrens Hospital Medical Center, will work with a multidisciplinary team to expand the patient cohort with plexiform neurofibromas and/or optic...